Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Figures and Graphics
Mueck AO et al.  
Comparison of Valsartan With Candesartan on Their Possible Protection From Atherosclerosis

Journal of Clinical and Basic Cardiology 2001; 4 (4): 297-299

PDF    Summary    Figures   


Figure
 
AII-Antagonisten - Atherosklerose
Figure 1: Changes in eNOS concentrations in endothelial cell cultures from human coronary artery after addition of angiotensin II alone (10 microM), angiotensin (10 microM) + candesartan, and angiotensin (10 microM) + valsartan as percentage of control value (= 100 %). (means +/- SD, triplicates from 2 different experiments, * p < 0.05, ** p < 0.01 vs A II; A II = angiotensin II; Can = candesartan; Val = valsartan)


Keywords: Angiotensin IIAngiotensin IICandesartanCandesartanDiagrammEndothelendotheliumeNOSeNOSValsartanValsartan
 
 
AII-Antagonisten - Atherosklerose
Figure 2: Changes in endothelin concentration in endothelial cell cultures from human coronary artery after addition of angiotensin II alone (10 microM), angiotensin (10 microM) + candesartan, and angiotensin (10 microM) + valsartan as percentage of control value = (100 %). (means +/- SD, triplicates from 2 different experiments, ** p < 0.01 vs A II; A II = angiotensin II; Can = candesartan; Val = valsartan)


Keywords: Angiotensin IIAngiotensin IICandesartanCandesartanDiagrammendothelinendothelinValsartanValsartan
 
 
AII-Antagonisten - Atherosklerose
Figure 3: Changes in PAI-1 concentration in endothelial cell cultures from human coronary artery after addition of angiotensin II alone (10 microM), angiotensin (10 microM) + candesartan, and angiotensin (10 microM) + valsartan as percentage of control value = (100 %). (means +/- SD, triplicates from 2 different experiments, * p < 0.05, ** p < 0.01 vs A II; A II = angiotensin II; Can = candesartan; Val = valsartan)


Keywords: Angiotensin IIAngiotensin IICandesartanCandesartanDiagrammPAI-1PAI-1plasminogen activator inhibitorPlasminogenaktivatorinhibitorValsartanValsartan
 
 
AII-Antagonisten - Atherosklerose
Figure 4: Changes in pro-MMP-1 concentration in endothelial cell cultures from human coronary artery after addition of angiotensin II alone (10 microM), angiotensin (10 microM) + candesartan, and angiotensin (10 microM) + valsartan as percentage of control value = (100 %). (means +/- SD, triplicates from 2 different experiments, * p < 0.05, ** p < 0.01 vs A II; A II = angiotensin II; Can = candesartan; Val = valsartan)


Keywords: Angiotensin IIAngiotensin IICandesartanCandesartanDiagrammmatrix-metalloproteinaseMatrixmetalloproteinasepro-MMP-1pro-MMP-1ValsartanValsartan
 
 
AII-Antagonisten - Atherosklerose
Figure 5: Changes in cell number of human coronary artery smooth muscle cells after addition of angiotensin II alone (10 microM), angiotensin (10 microM) + candesartan, and angiotensin (10 microM) + valsartan as percentage of control value = (100 %). (means +/- SD, triplicates from 2 different experiments, * p < 0.05, ** p < 0.01 vs A II; A II: angiotensin II; Can: candesartan; Val: valsartan)


Keywords: Angiotensin IIAngiotensin IICandesartanCandesartanDiagrammGlatte Muskelzellesmooth muscle cellValsartanValsartan
 
 
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung